Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
oleh: Kento Tomizawa, Ken Ando, Hirofumi Shimada, Takuya Kaminuma, Kazutoshi Murata, Takahiro Oike, Tatsuya Ohno
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-04-01 |
Deskripsi
Abstract Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose‐volume parameters for the rectum.